Agile Therapeutics, Inc.
AGRX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $3 | $3 | $3 | $3 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $5 | $5 | $3 | $4 |
| Inventory | $6 | $4 | $3 | $2 |
| Other Curr. Assets | $1 | $1 | $1 | $1 |
| Total Curr. Assets | $14 | $12 | $10 | $10 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $1 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $15 | $13 | $10 | $11 |
| Liabilities | – | – | – | – |
| Payables | $17 | $13 | $10 | $7 |
| Short-Term Debt | $0 | $0 | $2 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $9 | $8 | $9 | $8 |
| Total Curr. Liab. | $26 | $21 | $21 | $18 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $11 | $1 | $6 | $6 |
| Total NC Liab. | $11 | $1 | $6 | $6 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $1 |
| Total Liabilities | $37 | $23 | $27 | $23 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$434 | -$422 | -$423 | -$419 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $412 | $412 | $407 | $406 |
| Total Equity | -$22 | -$10 | -$16 | -$12 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $15 | $13 | $10 | $11 |
| Net Debt | -$3 | -$2 | -$0 | -$0 |